Torna al Registre Simple

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorConteduca, Vincenza
dc.contributor.authorJayaram, Anuradha
dc.contributor.authorRomero-Laorden, Nuria
dc.contributor.authorWetterskog, Daniel
dc.contributor.authorSalvi, Samanta
dc.contributor.authorGurioli, Giorgia
dc.contributor.authorMorales Barrera, Rafael
dc.date.accessioned2021-03-18T08:46:10Z
dc.date.available2021-03-18T08:46:10Z
dc.date.issued2019-03
dc.identifier.citationConteduca V, Jayaram A, Romero-Laorden N, Wetterskog D, Salvi S, Gurioli G, et al. Plasma Androgen Receptor and Docetaxel for Metastatic Castration-resistant Prostate Cancer. Eur Urol. 2019 Mar;75(3):368–73.
dc.identifier.issn0302-2838
dc.identifier.urihttps://hdl.handle.net/11351/5769
dc.descriptionCàncer de pròstata; Receptor d'andrògens; Docetaxel
dc.description.sponsorshipFunding/Support and role of the sponsor: V. Conteduca was funded by a European Society of Medical Oncology Translational Clinical Research Fellowship. A. Jayaram is supported by a grant from the Medical Research Council (MR/P002072/1). G. Attard is supported by a Cancer Research UK Advanced Clinician Scientist Grant (A22744). This work was funded in part by Prostate Cancer UK (PG12-49), the “Instituto de Salud Carlos III” (ISCII) PI16/01565 grant. E. Gonzalez-Billalabeitia was funded by a grant from the “Instituto de Salud Carlos III” (ISCIII) PI15/01499. N. RomeroLaorden was funded by a grant from the “Instituto de Salud Carlos III” (CM14-00200). E. Castro is supported by a Prostate Cancer Foundation Young Investigator Award (2017). E. Castro and D. Olmos are supported by grants from the Ministerio de Economía, Industria y Competitividad (JCI-2014-19129 to E.C., RYC-2015-18625 to D.O.). B. Mellado and M. Marin-Aguilera work were supported by the Instituto de Salud Carlos IIISubdirección General de Evaluación y Fomento de la Investigación (PI12/ 01226 and PI15/676) and co-funded by the European Regional Development Fund. Funding from CERCA Programme/Generalitat de Catalunya is gratefully acknowledged. During the conduct of the study, E. Castro was supported by a grant from the Ministerio de Educación, Cultura y Deportes (CAS17/00182). The funders of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding authors had full access to all data and had the final responsibility for the decision to submit for publication.
dc.language.isoeng
dc.publisherElsevier
dc.relation.ispartofseriesEuropean Urology;75(3)
dc.rightsAttribution 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.sourceScientia
dc.subjectPròstata - Càncer
dc.subjectMetàstasi
dc.subjectAntiandrògens
dc.subject.meshProstatic Neoplasms, Castration-Resistant
dc.subject.meshAndrogen Receptor Antagonists
dc.subject.meshDocetaxel
dc.titlePlasma Androgen Receptor and Docetaxel for Metastatic Castration-resistant Prostate Cancer
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.1016/j.eururo.2018.09.049
dc.subject.decsneoplasias prostáticas resistentes a la castración
dc.subject.decsantagonistas de andrógenos
dc.subject.decsdocetaxel
dc.relation.publishversionhttps://www.europeanurology.com/article/S0302-2838(18)30739-5/fulltext
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Conteduca V] Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy. Centre for Evolution and Cancer, The Institute of Cancer Research, London, UK. [Jayaram A] Centre for Evolution and Cancer, The Institute of Cancer Research, London, UK. The Royal Marsden NHS Foundation Trust, London, UK. University College London Cancer Institute, London, UK. [Romero-Laorden N] Prostate Cancer Clinical Research Unit, Spanish National Cancer Research Centre, Madrid, Spain. Hospital Universitario La Princesa, Madrid, Spain. [Wetterskog D] Centre for Evolution and Cancer, The Institute of Cancer Research, London, UK. University College London Cancer Institute, London, UK. [Salvi S, Gurioli G] Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy. [Morales R] Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain
dc.identifier.pmid30773204
dc.identifier.wos000458490100019
dc.relation.projectidinfo:eu-repo/grantAgreement/ES/PE2017-2020/PI16%2F01565
dc.relation.projectidinfo:eu-repo/grantAgreement/ES/PE2013-2016/PI15%2F01499
dc.relation.projectidinfo:eu-repo/grantAgreement/ES/PE2013-2016/PI15%2F676
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Fitxers en aquest element

Thumbnail

Aquest element apareix en la col·lecció o col·leccions següent(s)

Torna al Registre Simple